NTRA News and Press, Natera Inc. From 02/17/21

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced that the two companies have entered into a partnership in the field of personalized oncology. The partnership will pair P...

Natera to Participate in Upcoming Investor Conferences PR Newswire SAN CARLOS, Calif. , Feb. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Alexey Aleshin , MD, Natera's Sen...

Healthcare lagged the broader market last year, but that can change this year. A cyclical upturn as the pandemic abates and pent-up demand can boost healthcare. Best positioned are industry groups within healthcare that can achieve secular growth beyond the cyclical rise. Biot...

Panorama® SMART Study Confirms Market-Leading Performance in Largest Prospective NIPT Trial to Date Natera introduces Panorama AI, maintaining industry-leading sensitivity for identifying aneuploidies while dramatically lowering the no call rate PR Newswire SA...

SMART Study Finds 22q11.2 Microdeletion Prevalence Much Higher than Expected Natera introduces Panorama AI, improving upon its industry-leading detection for 22q11.2 microdeletions PR Newswire SAN CARLOS, Calif. , Feb. 1, 2021 /PRNewswire/ -- Natera, Inc. ...

Exact Sciences (EXAS), Natera (NTRA), Personalis (PSNL), and Veracyte (VCYT) are all trading sharply higher today, as Truist Securities initiates coverage with buy recommendations on the stocks.With a price target of $65 and ~21.4% of upside to the previous close, the only laggard in the list...

Natera Files Patent Infringement Suit Against Inivata PR Newswire SAN CARLOS, Calif. , Jan. 20, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed a lawsuit today against Inivata, Ltd. and its wholly-...

New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ Testing PR Newswire SAN CARLOS, Calif. , Jan. 14, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, tod...

Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium Oral presentation showcases the largest early-stage CRC cohort to date, further validating the serial use of Signatera™ for early recurrence detection and MRD assessment PR Newswire S...

It's hard to think of an industry that was more impacted by the 2020 COVID pandemic than diagnostics. The often-overlooked part of the healthcare system sprang into action, testing more than 250 million people last year in the U.S. alone. And interestingly, some testing companies performed ...